Stay updated with breaking news from Dddd L. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jammu and Kashmir Additional Chief Secretary (ACS) Agriculture Production Department (APD), Atal Dulloo on Monday chaired a meeting to discuss the permission and availability of petroleum-derived spray oils in the Union Territory.
24 May 2021 | 08:43am StockMarketWire.com - Pharmaceutical company 4D Pharma provided additional positive data from its completed phase 2 trial of LBP Blautix to treat irritable bowel syndrome with constipation or with diarrhea. 'Further analysis of the data has revealed strong and statistically significant activity on the key symptom of bowel habit, a potential approvable primary endpoint per regulatory guidelines,' the company said. 4D pharma previously announced topline efficacy and safety results from the trial, conducted in the US, UK and Ireland, in October 2020. In the post-hoc sub-gr...
1 March 2021 | 08:31am StockMarketWire.com - Pharmaceutical company 4D pharma said it had appointed John Beck as chief financial Officer. Most recently Beck was the senior vice president, finance and CFO of Ritter Pharmaceuticals from May 2018 to May 2020, where he oversaw its successful merger with Qualigen Therapeutics, Inc. At 8:31am: [LON:DDDD] 4d Pharma Plc Ord 0.25p share price was 0p at 95.6p Story provided by StockMarketWire.com Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Latest share price and company details:
8 February 2021 | 08:36am StockMarketWire.com - Pharmaceutical company 4D pharma said it had signed a clinical trial collaboration and supply agreement with Merck in Germany and Pfizer for an immunotherapy approved as a first-line maintenance treatment for patients with urothelial cancer. Bavencio was co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer. Under the collaboration, 4D pharma intended to commence a clinical trial in 2021 to evaluate Bavencio in combination with MRx0518 as a first-line maintenance therapy for 'patients with locally advanced or metastatic...